Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
Provided By PR Newswire
Last update: Nov 6, 2024
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile --
Read more at prnewswire.com
